Usen’s appointment follows the departure of Olav Bergheim, the company’s founder, CEO and board chair, effective Dec. 13. The company concurrently made Usen CEO and Orly Mishan chair of the board of directors. Bergheim intends to continue serving as an advisor and support Usen with the transition through Dec. 13, 2025.
“We are grateful to Olav for his dedication and contributions to Adagio. Under his leadership the company made substantial clinical and operational strides, and is NASDAQ-listed,” said Mishan. “We are extremely fortunate to add Todd, who has a breadth of commercial and operational experience and a proven track record leading large and complex medical device businesses, to the Adagio team. Todd has demonstrated exceptional leadership in building, restructuring, and growing public and private organizations. His efforts have been driven by a strong focus on corporate development, product innovation, logistics and go-to-market strategies.”
Usen’s track record includes the corner office at multiple companies. Most recently, he served as president and CEO of Minerva Surgical and, before that, he was CEO of Activ Surgical. Prior to his CEO posts, he led the Medical Systems Group at Olympus as president. Other roles include executive positions at Smith+Nephew and Boston Scientific.
He takes over the company as it advances its VT cryoablation system. Adagio built the VT system on its proprietary ultra-low-temperature cryoablation (ULTC) technology. It specifically designed VT to address both safety and effectiveness challenges of VT ablation. It does this by creating large and deep endocardial lesions with minimal attenuation by scar tissue without the need for catheter irrigation.
“I’m thrilled to join Adagio at this important junction in the company’s history, supporting initial commercial efforts in Europe, and the FULCRUM-VT trial enrollment in the United States,” said Usen. “With a growing body of evidence demonstrating both the safety and effectiveness of Adagio’s [ULTC] technology, and marked enthusiasm of users in both Europe and North America, I believe that Adagio’s VT cryoablation system with vCLAS catheter will become the future standard of care for treatment of patients with ventricular tachycardia.”
